EFFECT OF INFLAMMATION AND BENIGN PROSTATIC HYPERPLASIA ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS

EFFECT OF INFLAMMATION AND BENIGN PROSTATIC HYPERPLASIA ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS
复制标题

DOI:
10.1016/s0022-5347(01)67064-2
复制
发表时间:
1995-08-01
期刊:
影响因子:
6.6
通讯作者:
RATLIFF, TL
RATLIFF, TL
中科院分区:
医学1区
文献类型:
--
作者:
NADLER, RB;HUMPHREY, PA;RATLIFF, TL

文献摘要

被引文献

相似文献

目的:我们量化的原因,血清前列腺特异性抗原(PSA)浓度升高的男性前列腺活检反复显示没有cancer.Materials和Methods:前列腺体积,炎症,回声对超声和结石的影响进行了检查,在一个大型的PSA为基础的筛查人群的148名男性血清PSA浓度大于4.0 ng。毫升,直肠指检和多个阴性活组织检查结果怀疑为癌症。这些男性被选中,并与64名可疑直肠检查,多次阴性活检和血清PSA浓度为4.0 ng的男性进行比较。ml.结果:高PSA组前列腺体积较大(68对33 cc,p = 0.0001),亚临床前列腺炎症明显增多。急性和慢性炎症在高PSA组中更普遍(分别为63%与27%,p = 0.0001和99%与77%,p = 0.0001)。同步回归分析显示,前列腺大小、炎症、前列腺结石和非等回声超声病变分别占血清PSA变化的23%、7%、3%和1%。结论:前列腺体积和炎症是导致血清PSA升高的最重要因素。临床上没有检测到前列腺癌的男性。
Purpose: We quantify the causes of elevated serum prostate specific antigen (PSA) concentrations in men whose prostate biopsies repeatedly showed no cancer.Materials and Methods: The effects of prostate volume, inflammation, echogenicity on ultrasound and calculi were examined in a large PSA-based screening population of 148 men with serum PSA concentrations greater than 4.0 ng./ml., findings suspicious for cancer on digital rectal examination and multiple negative biopsies. These men were selected and compared to 64 men with suspicious rectal examinations, multiple negative biopsies and serum PSA concentrations of 4.0 ng./ml. or less.Results: The high PSA group had larger prostates (68 versus 33 cc, p = 0.0001) and significantly more subclinical prostatic inflammation. Acute and chronic inflammation was more prevalent in the high PSA group (63% versus 27%, p = 0.0001 and 99% versus 77%, p = 0.0001, respectively). A simultaneous regression analysis showed that prostatic size accounted for 23%, inflammation 7%, prostatic calculi 3% and nonisoechoic ultrasound lesions 1% of the serum PSA variance.Conclusions: Prostate volume and inflammation are the most important factors contributing to serum PSA elevation in men without clinically detectable prostate cancer.